141 related articles for article (PubMed ID: 28056490)
1. Knockout of the primary sclerosing cholangitis-risk gene Fut2 causes liver disease in mice.
Maroni L; Hohenester SD; van de Graaf SFJ; Tolenaars D; van Lienden K; Verheij J; Marzioni M; Karlsen TH; Oude Elferink RPJ; Beuers U
Hepatology; 2017 Aug; 66(2):542-554. PubMed ID: 28056490
[TBL] [Abstract][Full Text] [Related]
2. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
[TBL] [Abstract][Full Text] [Related]
3. Fut2 genotype is a risk factor for dominant stenosis and biliary candida infections in primary sclerosing cholangitis.
Rupp C; Friedrich K; Folseraas T; Wannhoff A; Bode KA; Weiss KH; Schirmacher P; Sauer P; Stremmel W; Gotthardt DN
Aliment Pharmacol Ther; 2014 Apr; 39(8):873-82. PubMed ID: 24612312
[TBL] [Abstract][Full Text] [Related]
4. Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model.
Lyoumi S; Abitbol M; Rainteau D; Karim Z; Bernex F; Oustric V; Millot S; Lettéron P; Heming N; Guillmot L; Montagutelli X; Berdeaux G; Gouya L; Poupon R; Deybach JC; Beaumont C; Puy H
Gastroenterology; 2011 Oct; 141(4):1509-19, 1519.e1-3. PubMed ID: 21762662
[TBL] [Abstract][Full Text] [Related]
5. Fucosyltransferase 2: a genetic risk factor for primary sclerosing cholangitis and Crohn's disease--a comprehensive review.
Maroni L; van de Graaf SF; Hohenester SD; Oude Elferink RP; Beuers U
Clin Rev Allergy Immunol; 2015 Jun; 48(2-3):182-91. PubMed ID: 24828903
[TBL] [Abstract][Full Text] [Related]
6. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
Miethke AG; Zhang W; Simmons J; Taylor AE; Shi T; Shanmukhappa SK; Karns R; White S; Jegga AG; Lages CS; Nkinin S; Keller BT; Setchell KD
Hepatology; 2016 Feb; 63(2):512-23. PubMed ID: 26172874
[TBL] [Abstract][Full Text] [Related]
8. Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation.
Jang JH; Rickenbacher A; Humar B; Weber A; Raptis DA; Lehmann K; Stieger B; Moritz W; Soll C; Georgiev P; Fischer D; Laczko E; Graf R; Clavien PA
Hepatology; 2012 Jul; 56(1):209-18. PubMed ID: 22290718
[TBL] [Abstract][Full Text] [Related]
9. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
[TBL] [Abstract][Full Text] [Related]
10. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis.
Fickert P; Stöger U; Fuchsbichler A; Moustafa T; Marschall HU; Weiglein AH; Tsybrovskyy O; Jaeschke H; Zatloukal K; Denk H; Trauner M
Am J Pathol; 2007 Aug; 171(2):525-36. PubMed ID: 17600122
[TBL] [Abstract][Full Text] [Related]
11. Bile canalicular abnormalities in the early phase of a mouse model of sclerosing cholangitis.
Miyao M; Ozeki M; Abiru H; Manabe S; Kotani H; Tsuruyama T; Tamaki K
Dig Liver Dis; 2013 Mar; 45(3):216-25. PubMed ID: 23107486
[TBL] [Abstract][Full Text] [Related]
12. Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis.
Wannhoff A; Rupp C; Friedrich K; Brune M; Knierim J; Flechtenmacher C; Sauer P; Stremmel W; Hov JR; Schirmacher P; Weiss KH; Gotthardt DN
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2372-9. PubMed ID: 26192140
[TBL] [Abstract][Full Text] [Related]
13. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
[TBL] [Abstract][Full Text] [Related]
14. Defective bile salt biosynthesis and hydroxylation in mice with reduced cytochrome P450 activity.
Kunne C; Acco A; Hohenester S; Duijst S; de Waart DR; Zamanbin A; Oude Elferink RP
Hepatology; 2013 Apr; 57(4):1509-17. PubMed ID: 23184615
[TBL] [Abstract][Full Text] [Related]
15. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
16. The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice.
Li X; Liu R; Yang J; Sun L; Zhang L; Jiang Z; Puri P; Gurley EC; Lai G; Tang Y; Huang Z; Pandak WM; Hylemon PB; Zhou H
Hepatology; 2017 Sep; 66(3):869-884. PubMed ID: 28271527
[TBL] [Abstract][Full Text] [Related]
17. Administration of Human MSC-Derived Extracellular Vesicles for the Treatment of Primary Sclerosing Cholangitis: Preclinical Data in MDR2 Knockout Mice.
Angioni R; Calì B; Vigneswara V; Crescenzi M; Merino A; Sánchez-Rodríguez R; Liboni C; Hoogduijn MJ; Newsome PN; Muraca M; Russo FP; Viola A
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238629
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.
Jones H; Hargrove L; Kennedy L; Meng F; Graf-Eaton A; Owens J; Alpini G; Johnson C; Bernuzzi F; Demieville J; DeMorrow S; Invernizzi P; Francis H
Hepatology; 2016 Oct; 64(4):1202-1216. PubMed ID: 27351144
[TBL] [Abstract][Full Text] [Related]
19. Knockout of the Tachykinin Receptor 1 in the Mdr2
Ceci L; Francis H; Zhou T; Giang T; Yang Z; Meng F; Wu N; Kennedy L; Kyritsi K; Meadows V; Wu C; Liangpunsakul S; Franchitto A; Sybenga A; Ekser B; Mancinelli R; Onori P; Gaudio E; Glaser S; Alpini G
Am J Pathol; 2020 Nov; 190(11):2251-2266. PubMed ID: 32712019
[TBL] [Abstract][Full Text] [Related]
20. The ascending pathophysiology of cholestatic liver disease.
Jansen PL; Ghallab A; Vartak N; Reif R; Schaap FG; Hampe J; Hengstler JG
Hepatology; 2017 Feb; 65(2):722-738. PubMed ID: 27981592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
